Drug Topics August 3, 2024
GLP-1 therapies are being evaluated to treat cardiovascular and kidney diseases in individuals with overweight or obesity.
The data are indisputable: across multiple phase 3 clinical trials, glucagon-like peptide-1 (GLP-1) therapies not only lead to weight loss, but can also confer protective effects against conditions such as cardiovascular and kidney diseases. For weight loss, GLP-1 medications suppress appetite and induce satiety; for cardiovascular disease, the mechanisms of action remain unknown.
“I think we still don’t completely understand how these drugs modify cardiovascular risk, particularly the risk of major adverse cardiovascular events,” said Ambarish Pandey, MD. Pandey, an associate professor of cardiology in internal medicine at the University of Texas Southwestern Medical Center in Dallas, Texas, sat down with Drug Topics...
Today's Sponsors
Today's Sponsor